» Articles » PMID: 16565723

Role of Matrix Metalloproteinases in Delayed Cortical Responses After Stroke

Overview
Journal Nat Med
Date 2006 Mar 28
PMID 16565723
Citations 349
Authors
Affiliations
Soon will be listed here.
Abstract

Matrix metalloproteinases (MMPs) are zinc-endopeptidases with multifactorial actions in central nervous system (CNS) physiology and pathology. Accumulating data suggest that MMPs have a deleterious role in stroke. By degrading neurovascular matrix, MMPs promote injury of the blood-brain barrier, edema and hemorrhage. By disrupting cell-matrix signaling and homeostasis, MMPs trigger brain cell death. Hence, there is a movement toward the development of MMP inhibitors for acute stroke therapy. But MMPs may have a different role during delayed phases after stroke. Because MMPs modulate brain matrix, they may mediate beneficial plasticity and remodeling during stroke recovery. Here, we show that MMPs participate in delayed cortical responses after focal cerebral ischemia in rats. MMP-9 is upregulated in peri-infarct cortex at 7-14 days after stroke and is colocalized with markers of neurovascular remodeling. Treatment with MMP inhibitors at 7 days after stroke suppresses neurovascular remodeling, increases ischemic brain injury and impairs functional recovery at 14 days. MMP processing of bioavailable VEGF may be involved because inhibition of MMPs reduces endogenous VEGF signals, whereas additional treatment with exogenous VEGF prevents MMP inhibitor-induced worsening of infarction. These data suggest that, contrary to MMP inhibitor therapies for acute stroke, strategies that modulate MMPs may be needed for promoting stroke recovery.

Citing Articles

The Triad of Blood-Brain Barrier Integrity: Endothelial Cells, Astrocytes, and Pericytes in Perinatal Stroke Pathophysiology.

Garcia-Martinez T, Gornatti D, Ortiz M, Canellas G, Heine-Suner D, Vives-Bauza C Int J Mol Sci. 2025; 26(5).

PMID: 40076511 PMC: 11900453. DOI: 10.3390/ijms26051886.


MMP-9 inhibitor SB-3CT improves neurological outcomes in ischemic stroke mice by modulation of astrocytic lipid metabolism.

Du L, Fang C, Wang Y, Feng Z, Abiola O, Gao Z Acta Pharmacol Sin. 2025; .

PMID: 40069489 DOI: 10.1038/s41401-025-01505-x.


Molecular Targeting of Ischemic Stroke: The Promise of Naïve and Engineered Extracellular Vesicles.

Lee J, Geum D, Park D, Kim J Pharmaceutics. 2025; 16(12.

PMID: 39771472 PMC: 11678501. DOI: 10.3390/pharmaceutics16121492.


A novel annexin dimer targets microglial phagocytosis of astrocytes to protect the brain-blood barrier after cerebral ischemia.

Tang W, Cheng R, Gao M, Hu M, Zhang L, Wang Q Acta Pharmacol Sin. 2024; .

PMID: 39663418 DOI: 10.1038/s41401-024-01432-3.


Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier.

Cazalla E, Cuadrado A, Garcia-Yague A Fluids Barriers CNS. 2024; 21(1):93.

PMID: 39574123 PMC: 11580557. DOI: 10.1186/s12987-024-00599-5.